Northland Securities Comments on Indivior Q1 Earnings

Indivior PLC (NASDAQ:INDV) – Northland Securities issued their Q1 2026 earnings per share (EPS) estimates for shares of Indivior in a report issued on Tuesday, January 20th. Northland Securities analyst C. Byrnes expects that the company will post earnings per share of $0.61 for the quarter. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share. Northland Securities also issued estimates for Indivior’s Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.69 EPS and FY2027 earnings at $3.10 EPS.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The firm had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million.

A number of other analysts have also commented on INDV. Craig Hallum reiterated a “buy” rating and issued a $41.00 price target on shares of Indivior in a research note on Friday, October 31st. Morgan Stanley reaffirmed an “overweight” rating and issued a $36.00 target price on shares of Indivior in a research report on Wednesday, December 3rd. Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. HC Wainwright raised their price target on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Indivior has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Indivior Stock Performance

Shares of NASDAQ:INDV opened at $33.54 on Wednesday. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of 36.46 and a beta of 0.75. The business has a 50-day simple moving average of $34.54 and a two-hundred day simple moving average of $27.04. Indivior has a fifty-two week low of $7.62 and a fifty-two week high of $38.00.

Institutional Trading of Indivior

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. boosted its stake in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock worth $79,757,000 after purchasing an additional 1,299,425 shares during the period. Jane Street Group LLC boosted its position in shares of Indivior by 2,597.9% during the first quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after acquiring an additional 958,132 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Indivior by 16.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after acquiring an additional 666 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new position in Indivior during the second quarter valued at $262,000. Finally, Y Intercept Hong Kong Ltd lifted its stake in Indivior by 17.4% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 25,443 shares of the company’s stock worth $375,000 after purchasing an additional 3,769 shares in the last quarter. Institutional investors own 60.33% of the company’s stock.

Insider Activity at Indivior

In other news, Director Mark Stejbach bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was bought at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director owned 16,847 shares of the company’s stock, valued at approximately $596,215.33. This represents a 4.82% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barbara Ryan purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. This trade represents a 65.24% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 4,871 shares of company stock worth $172,385 in the last 90 days.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.